TrialeLife2025

Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial.

Feilin Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.